Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.78 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.78 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.71 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL9818430 | 0.98 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL9032147 | 0.91 | CYSLTR1 (0.66) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL9032159 | 0.91 | CYSLTR1 (0.66) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL10547998 | 0.88 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL10543161 | 0.88 | CYSLTR1 (0.74) | CYSLTR1CYSLTR2GPBAR1PDE10AALOX5 | |
| SCHEMBL8734106 | 0.86 | PDE10A (0.66) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL3076102 | 0.86 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL4159309 | 0.85 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL10547699 | 0.85 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL10547475 | 0.85 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1183113-C | Tri-aryl acid derivatives as PPAR receptor ligands | ���ĵ�˹ҩ��¹�����˾ | 2005-01-05 | — | — | CN | disclosed |
| EP-0784052-B1 | Quinoline derivatives as antagonists of leukotriene d4, compositions containing the same and processes for their preparation | AVENTIS HOLDINGS INC (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| CN-1356983-A | Tri-aryl acid derivatives as PPAR receptor ligands | AVENTIS PHARM PROD INC (DE) | 2002-07-03 | — | — | CN | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| EP-0348155-B1 | Quinoline derivatives as antagonists of leukotriene D4, compositions containing the same and processes for their preparation | RHONE POULENC RORER INT (US) | 1999-05-12 | — | — | EP | disclosed |
| EP-0784052-A1 | Quinoline derivatives as antagonists of leukotriene d4, compositions containing the same and processes for their preparation | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5082849-A | Antiinflammatory agents or antiallergens | AVENTIS PHARMACEUTICALS INC. | 1992-01-21 | — | — | US | disclosed |
| US-4977162-A | Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments | RORER PHARMACEUTICAL CORPORATION (US) | 1990-12-11 | — | — | US | disclosed |
| US-4920131-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989012628-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0348155-A1 | Quinoline derivatives as antagonists of leukotriene D4, compositions containing the same and processes for their preparation | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4874769-A | LIPOXYGENASE INHIBITORS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-10-17 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0260305-A4 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS. | RORER INTERNAT OVERSEAS INC (US) | 1988-07-04 | — | — | EP | disclosed |
| EP-0260305-A1 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS. | RORER INT OVERSEAS (US) | 1988-03-23 | — | — | EP | disclosed |
| WO-1987005510-A1 | QUINOLINYL ETHER OR THIOETHER TETRAZOLES AS AGENTS FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-09-24 | — | — | WO | disclosed |